Getty Images

Using 14 points in the lungs, researchers looked for abnormalities and assigned each spot a score out of 3 based on its severity. Adding up all the points, they found the total lung ultrasound score was higher for those who had a worsening outcome of COVID-19. Image courtesy of Umberto Sabatini

Pre-treatment (A-C) and post-treatment (D-F) images after eight cycles of systemic FOLFIRINOX and consolidative chemoradiation. Baseline CA 19-9 was 145 U/ml. Pre-treatment whole body axial fused PET/MRI showed FDG avid lesion in body of pancreas (arrow, A) with SUVmax 7.1 and SUVgluc 8.0. Lesion was hypo-enhancing on axial contrast-enhanced T1-weighted (T1W) MR image (arrow, B) from focused abdominal PET/MRI and on CT (arrow, C). Pre-treatment CT tumor volume was 10.3 cm3. Post-treatment whole body axial fused PET/MRI showed complete metabolic response (arrow D) with SUVmax 1.9 and SUVgluc 1.9. Lesion was indistinct on axial contrast-enhanced T1W MRI (arrow, E) and CT (arrow, F), and there was upstream pancreatic parenchymal atrophy. Post-treatment CT tumor volume was 0.46 cm3. There was normalization of CA 19-9. Relative change in SUVmax (ΔSUVgluc) was -73%, and relative change in SUVgluc (ΔSUVgluc) was -76%. Based on change in tumor size, response was categorized as partial response per RECIST. Relative change in tumor volume (ΔTvol) was -96%. Pathology showed major pathologic response (College of American Pathologists score 1.) Images courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

An MR image of a patient in their early 20s shows nerve injury (highlighted in yellow) of the left brachial plexus in the neck. The patient experienced left arm weakness and pain after recovering from COVID-19 respiratory illness, which prompted them to see their primary care physician. As a result of the MRI findings, the patient was referred to the COVID-19 neurology clinic for treatment. Image courtesy of Northwestern University

Image courtesy of Toshiba/Canon